Comparative Pharmacology
Head-to-head clinical analysis: DDAVP versus DDAVP NEEDS NO REFRIGERATION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP versus DDAVP NEEDS NO REFRIGERATION.
DDAVP vs DDAVP (NEEDS NO REFRIGERATION)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog